Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 7/20 | 0.49 |
| ▸ | TERT | O14746 | 3/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113769 | 0.93 | P2RY12 (0.53) | P2RY12HTR3ATERTGAAKMT2A | |
| SCHEMBL9922461 | 0.92 | P2RY12 (0.64) | P2RY12HTR3ATERTCACNA1G | |
| SCHEMBL9922508 | 0.91 | P2RY12 (0.63) | P2RY12HTR3ATERTCACNA1GGAA | |
| SCHEMBL9922853 | 0.90 | P2RY12 (0.50) | P2RY12HTR3ATERTCACNA1GHRH3 | |
| SCHEMBL14113575 | 0.90 | P2RY12 (0.51) | P2RY12HTR3ATERTGAAKMT2A | |
| SCHEMBL12177238 | 0.90 | P2RY12 (0.49) | P2RY12HTR3ATERTCACNA1GHRH3 | |
| SCHEMBL14228343 | 0.90 | P2RY12 (0.46) | P2RY12HTR3ATERTCACNA1GHRH3 | |
| SCHEMBL9922665 | 0.88 | P2RY12 (0.62) | P2RY12HTR3ATERTCACNA1GHRH3 | |
| SCHEMBL12177205 | 0.88 | P2RY12 (0.58) | P2RY12HTR3AGAAKMT2AALDH1A1 | |
| SCHEMBL14113679 | 0.88 | P2RY12 (0.56) | P2RY12HTR3ATERTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | P2RY12 89/4885HTR3A 2487/4885TERT 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.